WO2010058824A1 - Substance pour réguler la différenciation dans des cellules mésenchymateuses, et utilisation de celle-ci - Google Patents

Substance pour réguler la différenciation dans des cellules mésenchymateuses, et utilisation de celle-ci Download PDF

Info

Publication number
WO2010058824A1
WO2010058824A1 PCT/JP2009/069654 JP2009069654W WO2010058824A1 WO 2010058824 A1 WO2010058824 A1 WO 2010058824A1 JP 2009069654 W JP2009069654 W JP 2009069654W WO 2010058824 A1 WO2010058824 A1 WO 2010058824A1
Authority
WO
WIPO (PCT)
Prior art keywords
differentiation
mirna
mesenchymal
mesenchymal cells
strand
Prior art date
Application number
PCT/JP2009/069654
Other languages
English (en)
Japanese (ja)
Inventor
伊藤　智広
赤尾　幸博
三島　敏
幸夫 北出
Original Assignee
国立大学法人岐阜大学
財団法人岐阜県研究開発財団
アピ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人岐阜大学, 財団法人岐阜県研究開発財団, アピ株式会社 filed Critical 国立大学法人岐阜大学
Priority to JP2010539252A priority Critical patent/JP5794559B2/ja
Publication of WO2010058824A1 publication Critical patent/WO2010058824A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • a benzyl derivative such as dimethyl phthalate or dimethyl pyridinedicarboxylate is reduced, followed by DMTr, which is further amidated with an amidite reagent to obtain an amidite.
  • a DMTr body can be succinylated and further combined with a CPG resin to obtain a CPG derivative.
  • a suitable protecting group is added to the hydroxyl group provided in the benzyl derivative or the like, and deprotection is performed at an appropriate stage after the coupling of the base and before DMTr formation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un régulateur qui peut agir sur le processus de différenciation d’un ostéoblaste ou similaire, spécifiquement pour réguler la différenciation de l’ostéoblaste ou similaire. La présente invention concerne en outre l’utilisation du régulateur. La présente invention concerne spécifiquement un régulateur pour la différenciation dans une cellule mésenchymateuse, qui comprend une substance active choisie parmi un miARN qui peut se lier à une région non traduite en 3' dans le gène Dlx5, un précurseur du miARN, une construction d’ADN qui code pour le miARN ou le précurseur du miARN, et un inhibiteur du miARN.
PCT/JP2009/069654 2008-11-19 2009-11-19 Substance pour réguler la différenciation dans des cellules mésenchymateuses, et utilisation de celle-ci WO2010058824A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010539252A JP5794559B2 (ja) 2008-11-19 2009-11-19 間葉系細胞の分化を調節するための薬剤及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-296166 2008-11-19
JP2008296166 2008-11-19

Publications (1)

Publication Number Publication Date
WO2010058824A1 true WO2010058824A1 (fr) 2010-05-27

Family

ID=42198263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/069654 WO2010058824A1 (fr) 2008-11-19 2009-11-19 Substance pour réguler la différenciation dans des cellules mésenchymateuses, et utilisation de celle-ci

Country Status (2)

Country Link
JP (1) JP5794559B2 (fr)
WO (1) WO2010058824A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013091611A (ja) * 2011-10-25 2013-05-16 Gifu Univ 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
JPWO2016104775A1 (ja) * 2014-12-27 2017-08-24 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
CN107189985A (zh) * 2017-07-24 2017-09-22 中国人民解放军军事医学科学院基础医学研究所 miRNA分子及其抑制剂在调控骨间充质干细胞成脂分化中的应用
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
US10934542B2 (en) 2013-12-27 2021-03-02 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094135A1 (fr) * 2006-02-15 2007-08-23 Gifu University Derive d'oligonucleotide et son utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094135A1 (fr) * 2006-02-15 2007-08-23 Gifu University Derive d'oligonucleotide et son utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GREGORY, P.A. ET AL.: "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1", NAT CELL BIOL, vol. 10, no. 5, May 2008 (2008-05-01), pages 593 - 601 *
ITOH, T. ET AL.: "MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5", J BIOL CHEM, vol. 284, no. 29, 2009, pages 19272 - 9 *
LEE, M.H. ET AL.: "BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression", J BIOL CHEM, vol. 278, no. 36, 2003, pages 34387 - 94 *
PALMIERI, A. ET AL.: "Calcium sulfate acts on the miRNA of MG63E osteoblast-like cells", J BIOMED MATER RES B APPL BIOMATER, vol. 84, no. 2, February 2008 (2008-02-01), pages 369 - 74 *
TOMOHIRO ITO ET AL.: "MicroRNA-141, -200a ni yoru BMP-2 Yudo Mouse Zenku Kotsuga Saibo no Bunka Chosetsu", DAI 31 KAI ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN KOEN YOSHISHU, 4 December 2008 (2008-12-04), pages 2P-0794 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013091611A (ja) * 2011-10-25 2013-05-16 Gifu Univ 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
US10934542B2 (en) 2013-12-27 2021-03-02 Bonac Corporation Artificial match-type miRNA for controlling gene expression and use therefor
JPWO2016104775A1 (ja) * 2014-12-27 2017-08-24 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
CN107189985A (zh) * 2017-07-24 2017-09-22 中国人民解放军军事医学科学院基础医学研究所 miRNA分子及其抑制剂在调控骨间充质干细胞成脂分化中的应用
CN107189985B (zh) * 2017-07-24 2021-02-02 中国人民解放军军事医学科学院基础医学研究所 miRNA分子及其抑制剂在调控骨间充质干细胞成脂分化中的应用

Also Published As

Publication number Publication date
JP5794559B2 (ja) 2015-10-14
JPWO2010058824A1 (ja) 2012-04-19

Similar Documents

Publication Publication Date Title
AU2021203174A1 (en) Compositions and methods for modulating RNA
CA2977624C (fr) Composition pharmaceutique pour le traitement du cancer comprenant un micro-arn en tant que principe actif
CA2970801C (fr) Acides nucleiques double brin modifies par un ligand
EP2427472B1 (fr) Conjugués polynucléotidiques lipophiles
JP5816556B2 (ja) 治療剤のためのｕｎａオリゴマー構造
DK2612917T3 (en) Antisense nucleic acid
ES2618203T3 (es) Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral
JP5963680B2 (ja) 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
US20110152352A1 (en) Smad proteins control drosha-mediated mirna maturation
JP5794559B2 (ja) 間葉系細胞の分化を調節するための薬剤及びその利用
KR20100126430A (ko) 진단 및 치료 목적을 위한 마이크로ｒｎａ 및 다운스트림 타겟
EP3394259B1 (fr) Compositions et méthodes pour diminuer l'expression de tau
EP2298359A1 (fr) Acide nucléique capable de réguler la dégranulation d'un mastocyte
CN112513273A (zh) 用于调节scn9a表达的寡核苷酸
EA031110B1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
JP2021526797A (ja) Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
EP2781598B1 (fr) Molécule d'acide nucléique pour inhiber l'activité de molécule arni
JP5850702B2 (ja) 間葉系細胞の分化調節剤およびこれを用いた医薬、並びに間葉系細胞への分化調節作用を有する物質のスクリーニング方法
US20140194491A1 (en) Modulation of microrna-138 for the treatment of bone loss
EP3423581A1 (fr) Ciblage de micro-arn pour le traitement du cancer
KR101286154B1 (ko) 안티센스 올리고뉴클레오타이드를 포함하는 줄기세포로부터 연골세포 분화 촉진용 및 항암 약제학적 조성물
CN115103911A (zh) 修饰的异源核酸
JP2021519261A (ja) 細胞リプログラミングのための組成物および方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827605

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2010539252

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09827605

Country of ref document: EP

Kind code of ref document: A1